Twenty-nine patients with primary brain tumors recurrent or progressive after cerebral irradiation were treated with AZQ. Twenty of the 29 patients had also failed prior chemotherapy. CT scan-documented tumor regressions were noted in 17.2% (5/29) and ranged from 15.0% (3/20) in patients with prior chemotherapy to 22.2 (2/9) in patients without prior chemotherapy. Myelosuppression was the only significant toxicity noted. AZQ is worthy of further studies in patients with primary brain tumors.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
primary brain
12
brain tumors
12
prior chemotherapy
12
tumors recurrent
8
patients primary
8
patients prior
8
patients
5
preliminary communication--treatment
4
communication--treatment primary
4
recurrent irradiation
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!